Vaxcyte prices $500M equity offering and $500M convertible notes

Vaxcyte announced a $500M equity offering and $500M in convertible notes. The notes have a 1.50% interest rate, mature in 2032, and include a 40% conversion premium at $89.60 per share. They can be converted, repurchased, or redeemed under certain conditions.

Original reporting
Published Oct 7, 2026, 5:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 5:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vaxcyte prices $500M equity offering and $500M convertible notes — source image
Decision brief

The 30-second read

High
01

Why it matters

The $1B combined equity and convertible note offering provides runway for late‑stage trials, but the conversion premium and dilution may pressure the stock in the short term.

02

Market read

The announcement is a primary market‑moving event for Vaxcyte, likely to trigger immediate price action and set a financing precedent for similar biotech firms.

03

What to watch

Potential strategic partnership or licensing deals that may accompany the capital raise are not disclosed.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Vaxcyte is a clinical‑stage biotech developing vaccine platforms; the company previously raised capital through smaller private placements.

Market effects

Biotech financing activity may signal investor appetite for pipeline funding, influencing peer fundraising.

US biotech sector could see modest volatility as investors assess dilution risk.

Limited; primarily affects Vaxcyte and comparable biotech issuers.

Counterpoint

The raise could be seen as a vote of confidence, suggesting upcoming positive trial data that outweighs dilution concerns.

Key entities

  • Vaxcyte

    Clinical‑stage biotech focused on vaccine development.

  • Investors in the offering

    Entities purchasing the new equity and convertible notes.

Related articles

HighAI 9/10

Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals

Vaxcyte's VAX-31 pneumococcal vaccine met all primary endpoints in the phase 3 OPUS-1 trial, showing noninferior immune responses to existing vaccines and superior responses for unique serotypes. The trial enrolled 4,047 adults and demonstrated safety with mostly mild reactions. Vaxcyte plans to submit a BLA in 2028, with additional data expected in 2027. The vaccine aims to cover 86.7% of adult nonbacteremic pneumonia and 93.9% of adult IPD, addressing a significant healthcare burden.

$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety P

$PCVXHighAI 8/10

Vaxcyte’s vaccine candidate met every main goal in a trial of 4,047 adults. More trial results are expected in 2027.

Vaxcyte's VAX-31 vaccine met all primary endpoints in a Phase 3 trial of 4,047 adults, showing safety and efficacy. The company plans to report more trial results in 2027 and submit a BLA in 2028. VAX-31 is designed to prevent pneumococcal disease. Vaxcyte also announced progress in its VAX-A1 vaccine candidate for Group A Streptococcus.